Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 4/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | TNKS | O95271 | 2/20 | 0.73 |
| ▸ | PARP1 | P09874 | 2/20 | 0.73 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.73 |
| ▸ | CASP3 | P42574 | 1/20 | 0.73 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.73 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.73 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.64 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29784145 | 1.00 | GUSB (0.73) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL28645325 | 0.89 | GUSB (0.77) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL27694110 | 0.86 | NPC1 (0.61) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL8620410 | 0.85 | TNKS (0.83) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL13011773 | 0.85 | GUSB (0.75) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL17786622 | 0.85 | NPC1 (0.59) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL259622 | 0.85 | KDM4C (0.55) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL27694097 | 0.85 | TNKS (0.58) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL259479 | 0.85 | ALDH1A1 (0.64) | GUSBNPC1RAB9ATNKSPARP1 | |
| SCHEMBL259476 | 0.85 | KDM4C (0.66) | GUSBNPC1RAB9ATNKSPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113563272-B | Preparation method of 2-phenylquinazolinone compound | 三峡大学 | 2023-03-10 | — | — | CN | disclosed |
| CN-109879820-B | Synthetic method of quinazolinone heterocyclic compound | 扬州大学 | 2022-07-19 | — | — | CN | disclosed |
| CN-113563272-A | Preparation method of 2-phenylquinazolinone compound | 三峡大学 | 2021-10-29 | — | — | CN | disclosed |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX LLC (US) | 2021-01-21 | — | — | US | disclosed |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX LLC (US) | 2021-01-21 | — | — | US | disclosed |
| US-10570123-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570123-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2018-03-15 | — | — | US | disclosed |
| WO-2012040499-A2 | METABOLIC INHIBITORS | SURFACE LOGIX, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| EP-2406236-A1 | RHO KINASE INHIBITORS | Surface Logix, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010104851-A1 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20100144707-A1 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100144707-A1 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100144707-A1 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2008054599-A2 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008054599-A2 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-1865958-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | Surface Logix, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105081-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | GUSB 895/4885NPC1 238/4885RAB9A 455/4885 |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | GUSB 895/4885NPC1 238/4885RAB9A 455/4885 |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | GUSB 895/4885NPC1 238/4885RAB9A 455/4885 |
| US-20100144707-A1 | Pharmacokinetically improved compounds | ROCK2, ROCK1, RHOT2 | GUSB 895/4885NPC1 238/4885RAB9A 455/4885 |
| US-10570123-B2 | Pharmacokinetically improved compounds | ROCK2, ROCK1, RHOT2 | GUSB 895/4885NPC1 238/4885RAB9A 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.